Thu, Aug 1, 9:23 PM (88 days ago)
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced on August 1, 2024, that CenExel, a nationwide clinical research site network, will conduct a method comparison clinical study as part of the company's FDA 510(k) clinical study plan. This announcement was made via a press release, which is incorporated by reference into the company's Form 8-K filing. The press release and related information are provided for regulatory disclosure purposes and are not deemed to be filed under the Securities Exchange Act of 1934 or the Securities Act of 1933. The company's principal executive office is located at 135 West 41st Street, 5th Floor, New York, NY 10036, with a former address at 142 West 57th Street, 11th Floor, New York, NY 10019. The report was signed by Spiro Sakiris, the Chief Financial Officer of Intelligent Bio Solutions Inc.